$LAB News
Last published 1w ago
- 1w agoLABARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark ScientificGlobeNewswireBOSTON, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Global private equity healthcare specialist ARCHIMED, and Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools"), today announced the completion of
- 3mo agoLABStandard BioTools Reports Second Quarter 2026 Financial ResultsGlobeNewswireBOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the quarter ended June 30, 2026.
- 3mo agoLABStandard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline BiosciencesGlobeNewswireSale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms
- 3mo agoLABStandard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026GlobeNewswireBOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market
- 3mo agoLABStandard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences TransactionGlobeNewswireHighlights combined company’s strong financial position with over $900 million expected at closing, Treeline’s deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program
- 5mo agoFLDMLABStandard BioTools Corporate UpdateSTANDARD BIOTOOLS INCEarnings Call TranscriptsThank you for joining the Standard BioTools and Treeline Biosciences Merger Announcement Conference call. I would now like to turn the call over to John Graziano, Standard Bio Tools Vice President of Investor Relations.
- 5mo agoLABStandard BioTools and Treeline Biosciences Announce Merger AgreementGlobeNewswireCombined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates Company to be led by Treeline CEO and
- 6mo agoLABStandard BioTools Reports First Quarter 2026 Financial ResultsGlobeNewswireBOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the quarter ended March 31, 2026. Recent Highlights:
- 6mo agoLABStandard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026GlobeNewswireBOSTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U.S. market close.
- 8mo agoLABStandard BioTools Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireBOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the quarter and fiscal year ended December 31, 2025.
- 9mo agoLABStandard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026GlobeNewswireBOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S.
- 9mo agoILMNLABStandard BioTools Completes Sale of SomaLogic to IlluminaGlobeNewswireReceived $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close,
- 10mo agoLABStandard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 RevenueGlobeNewswireBOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools" or the "Company") today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025.
- 11mo agoLABMolecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass CytometryBusiness WireAdvancing next-generation IMC workflows with class-leading HCR imaging technologies for greater sensitivity and flexibility Molecular Instruments® (MI), the inventor of the HCR™ imaging platform, and
- 1y agoILMNLABIllumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanksPR NewswireIllumina, Inc. (NASDAQ: ILMN) today announced that Illumina Protein Prep is delivering the broadest coverage of the blood proteome on the market at...
- 1y agoLABStandard BioTools Reports Third Quarter 2025 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the quarter ended September 30, 2025.
- 1y agoLABStandard BioTools to Announce Third Quarter Financial Results on November 4, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025, after U.S.
- 1y agoILMNLABIllumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and developmentPR NewswireIllumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation...
- 1y agoILMNLABIllumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and developmentPR NewswireIllumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation...
- 1y agoLABStandard BioTools Reports Second Quarter 2025 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the second quarter ended June 30, 2025.
- 1y agoLABStandard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health StudyGlobeNewswirePRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan's strategic position in the high-impact biobank segment and its increasing role in leading
- 1y agoLABStandard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market
- 1y agoILMNLABIllumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategyPR NewswireIllumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina...
- 1y agoILMNLABStandard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to IlluminaGlobeNewswireUp To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent
- 1y agoLABStandard BioTools to Host Inaugural "Proteomics Roundtable" Webcast SeriesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced the launch of its inaugural Proteomics Roundtable Series – a program of virtual events designed to spark
- 1y agoLABStandard BioTools Reports First Quarter 2025 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025.
- 1y agoLABStandard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025GlobeNewswireExpanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic
- 1y agoLABStandard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close.
- 1y agoLABStandard BioTools to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that company management will participate in the following investor conferences: TD Cowen's 45th Annual
- 1y agoLABStandard BioTools Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the fourth quarter and fiscal year ended
- 1y agoLABStandard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26,
- 1y agoLABStandard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 RevenueGlobeNewswirePreliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m. PT. SOUTH SAN
- 1y agoLABStandard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature MedicineGlobeNewswireSOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company") announced today that its SomaScan™ Platform played a pivotal role in a study published in the
- 1y agoLABStandard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd
- 2y agoLABStandard BioTools Appoints Alex Kim as Chief Financial OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer,
- 2y agoLABStandard BioTools to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that its management team will participate in the following investor conferences in the month of
- 2y agoLABStandard BioTools Inc. (LAB) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoLABStandard BioTools Reports Third Quarter 2024 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company") today announced unaudited interim financial results for the third quarter ended September 30, 2024.
- 2y agoLABStandard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the
- 2y agoLABStandard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K PlatformGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), today announced that the SomaScan® 11K Platform now includes protein measurements on a broader range of sample
- 2y agoLABStandard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced a recent paper published in Nature Scientific Reports, by researchers at Pfizer Research and
- 2y agoLABStandard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming Morgan
- 2y agoLABStandard BioTools to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), today announced that its management team will participate in the following investor conferences in the month of
- 2y agoLABStandard BioTools Inc. (LAB) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoLABStandard BioTools Announces Senior Leadership ChangesGlobeNewswireAlex Kim, Chief Operating Officer and Standard BioTools Co-Founder, to Serve as interim Chief Financial Officer Following Departure of Jeffrey Black on August 31, 2024 Industry Veteran Sean Mackay Named Chief Business
- 2y agoLABStandard BioTools Reports Second Quarter 2024 Financial ResultsGlobeNewswireDelivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024 Revised FY2024 revenue guidance; on-track to achieve anticipated break-even adjusted EBITDA
- 2y agoLABStandard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced that it will report second quarter 2024 financial results
- 2y agoLABStandard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan CustomersGlobeNewswireSOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it has purchased the LSAXT system from Carterra®, a leading provider of
- 2y agoLABStandard BioTools to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools") (NASDAQ:LAB) today announced that its management team will participate in the following investor conferences in
- 2y agoLABStandard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools") (NASDAQ:LAB) today announced that the Human Capital Committee of its Board of Directors, which is composed